Loading data for IMDX — first visit, this takes a few seconds.

Alerta

Insight Molecular Diagnos... (IMDX)

NasdaqCM: IMDX · Precio en tiempo real · USD

4.38

+0.10 (2.34%)

Al cierre: Aug 19, 2026, 4:20 PM

2.34% (1D)

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	143.5M
Ingresos (TTM)	1.67M
Beneficio neto (TTM)	-49.36M
Beta	1.82
EPS (TTM)	-1.52
Ratio PER (TTM)	n/a
Adelante PE	-5.22
P/B (TTM)	-6.72
P/S (TTM)	85.93
Earnings Date	Nov 9, 2026

Precio de venta	n/a
Volumen	25,364
Volumen medio (20D)	246,801
Abierto	4.29
Anterior Cerrar	4.28
Rango del día	4.25 - 4.46
Rango de 52 semanas	2.33 - 8.51
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de IMDX

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment...

[Leer más]

Industria Diagnostics & Research

Sector Healthcare

IPO Fecha Dec 30, 2015

Empleados 55

Bolsa de Valores NasdaqCM

Símbolo bursátil IMDX

Sitio web https://www.imdxinc.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Insight Molecular Diagnostics fueron 4.05M, un aumento de 115.58% en comparación con 1.88M del año anterior. Las ganancias fueron -50.22M, una disminución de -17.21%.

Estados financieros

Sorpresa de resultados

Insight Molecular Diagnostics ha publicado sus resultados trimestrales en Aug 10, 2026:

Ingresos de $32K falla las estimaciones por $0, con -98.50% Disminución interanual.

EPS de -0.24 falla las estimaciones por -0.01, con 20.00% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Insight Molecular Diagnostics Inc. publique sus resultados el Nov 9, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Moby

Insight Molecular Diagnostics Inc. Q2 2026 Earnings Call Summary

Moby summary of Insight Molecular Diagnostics Inc.'s Q2 2026 earnings call

1 semana hace · MarketBeat

Oncocyte Q2 Earnings Call Highlights

Oncocyte (NASDAQ:IMDX) executives said they continue to target FDA marketing authorization for the GraftAssureDx kidney-transplant rejection test later this year, while preparing for a commercial laun...

2 meses hace · Insider Monkey

Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment

Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) is one of the high-growth micro-cap stocks to buy now. On June 11, Insight Molecular Diagnostics Inc. (NASDAQ:IMDX) announced the online publication in...

3 meses hace · Simply Wall St.

How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission

Insight Molecular Diagnostics now sits under a refreshed analyst narrative, with a price target that has moved to US$12 per share alongside an updated fair value estimate of US$10.50. Analysts linking...

3 meses hace · Moby

Insight Molecular Diagnostics Inc. Q1 2026 Earnings Call Summary

Moby summary of Insight Molecular Diagnostics Inc.'s Q1 2026 earnings call

Página 1 de 2